Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine in Vaginal Hysterectomy
NCT03907033Phase 4Terminated
- Sponsor
- Mayo Clinic
- Start
- Sep 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of liposomal bupivacaine in postoperative pain (2 arms), sponsored by Mayo Clinic. Primary endpoints: Total Post-surgical Opioid Medication Use at 72 hours and Total Post-surgical Analgesic Medication Use at 72 hours. Started Sep 2019; status: terminated.
02
Drugs
liposomal bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03907033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03907033.